SG/CALL/MODERNA/145/0.1/20.12.24 | Real-time Euronext Paris 11:09:07 2024-05-14 EDT | ||
| 1.535 EUR | +20.39% |
|
| Current month | +28.14% | ||
| 1 month | +39.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-14 | 1.535 | +20.39% |
| 24-05-13 | 1.275 | +17.51% |
| 24-05-10 | 1.085 | -17.49% |
| 24-05-09 | 1.315 | +9.13% |
| 24-05-08 | 1.205 | +6.17% |
Real-time Euronext Paris
Last update May 14, 2024 at 11:09 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| 8D14S | |
| ISIN | DE000SW7MWM0 |
| Date issued | 2024-03-12 |
| Strike | 145 $ |
| Maturity | 2024-12-20 (220 Days) |
| Parity | 10 : 1 |
| Emission price | 1.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.595 € |
|---|---|
| Lowest since issue | 0.685 € |
| Spread | 0.01 € |
| Spread % | 0.64% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
125.7
USD
Average target price
138.5
USD
Spread / Average Target
+10.22%
- Stock Market
- Warrants
- 8D14S Warrant